CA2466118A1 - Modulation of lir function to treat rheumatoid arthritis - Google Patents

Modulation of lir function to treat rheumatoid arthritis Download PDF

Info

Publication number
CA2466118A1
CA2466118A1 CA002466118A CA2466118A CA2466118A1 CA 2466118 A1 CA2466118 A1 CA 2466118A1 CA 002466118 A CA002466118 A CA 002466118A CA 2466118 A CA2466118 A CA 2466118A CA 2466118 A1 CA2466118 A1 CA 2466118A1
Authority
CA
Canada
Prior art keywords
lir
ser
leu
pro
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002466118A
Other languages
English (en)
French (fr)
Inventor
Jonathan P. Arm
Nicodemus Tedla
Luis G. Borges
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Brigham and Women's Hospital Inc
Immunex Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2466118A1 publication Critical patent/CA2466118A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002466118A 2001-11-14 2002-11-12 Modulation of lir function to treat rheumatoid arthritis Abandoned CA2466118A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33589901P 2001-11-14 2001-11-14
US60/335,899 2001-11-14
PCT/US2002/036372 WO2003041650A2 (en) 2001-11-14 2002-11-12 Modulation of lir function to treat rheumatoid arthritis

Publications (1)

Publication Number Publication Date
CA2466118A1 true CA2466118A1 (en) 2003-05-22

Family

ID=30770813

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002466118A Abandoned CA2466118A1 (en) 2001-11-14 2002-11-12 Modulation of lir function to treat rheumatoid arthritis

Country Status (8)

Country Link
US (1) US20050238643A1 (cg-RX-API-DMAC10.html)
EP (1) EP1453540A4 (cg-RX-API-DMAC10.html)
JP (1) JP2005532256A (cg-RX-API-DMAC10.html)
AU (1) AU2002360376B2 (cg-RX-API-DMAC10.html)
CA (1) CA2466118A1 (cg-RX-API-DMAC10.html)
MX (1) MXPA04004491A (cg-RX-API-DMAC10.html)
PL (1) PL374463A1 (cg-RX-API-DMAC10.html)
WO (1) WO2003041650A2 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255121A1 (en) * 2004-11-02 2008-10-16 Dainippon Sumitomo Pharma Co., Ltd. Combination Drug for Treating Autoimmune Disease
GB0510627D0 (en) 2005-05-25 2005-06-29 Avidex Ltd Polypeptides
ES2547463T3 (es) 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. Moléculas de unión a ILT3 y usos de las mismas
WO2008094176A2 (en) 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
AU2009246443A1 (en) * 2008-05-13 2009-11-19 Genentech, Inc. Anti-PirB antibodies
US20120094914A1 (en) * 2009-03-03 2012-04-19 Kyushu University, National University Corporation Prophylactic or therapeutic agent for rheumatoid arthritis or rheumatoid arthritis-related diseases
JP5947727B2 (ja) * 2010-01-20 2016-07-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節
AU2011207253B2 (en) * 2010-01-20 2015-02-12 Merck Sharp & Dohme Corp. Anti-ILT5 antibodies and ILT5-binding antibody fragments
CA2888647A1 (en) * 2012-11-20 2014-05-30 Revive Therapeutics Inc. The use of bucillamine in the treatment of gout
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
EP4219559A3 (en) 2017-12-22 2023-10-18 Jounce Therapeutics, Inc. Antibodies for lilrb2
MY201995A (en) 2018-07-09 2024-03-28 Five Prime Therapeutics Inc Antibodies binding to ilt4
KR20220154686A (ko) * 2020-02-12 2022-11-22 바이오인벤트 인터내셔날 에이비 Lilrb3 항체 분자 및 이의 용도
CA3181197A1 (en) 2020-05-01 2021-11-04 NGM Biopharmaceuticals, Inc Ilt-binding agents and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001509030A (ja) * 1997-01-21 2001-07-10 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Ｆｃレセプターおよびポリペプチド
US6384203B1 (en) * 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6448035B1 (en) * 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
WO2001055335A2 (en) * 2000-01-25 2001-08-02 Hyseq, Inc. Methods and materials relating to leukocyte immunoglobulin receptor-like (lir-like) polypeptides and polynucleotides

Also Published As

Publication number Publication date
WO2003041650A2 (en) 2003-05-22
EP1453540A4 (en) 2005-06-01
PL374463A1 (en) 2005-10-17
EP1453540A2 (en) 2004-09-08
WO2003041650A3 (en) 2004-01-29
US20050238643A1 (en) 2005-10-27
AU2002360376B2 (en) 2006-05-18
MXPA04004491A (es) 2005-05-16
JP2005532256A (ja) 2005-10-27

Similar Documents

Publication Publication Date Title
AU781998B2 (en) Receptor on the surface of activated T-cells: ACTS-4
CA2318405C (en) Antibodies to death receptor 4(dr4) and uses thereof
JP3703834B2 (ja) 活性化ｃｄ４▲上＋▼ｔ細胞の表層上のレセプターに対するリガンド（ａｃｔ−４−ｌ）
US6372899B1 (en) Purified genes encoding mammalian cell surface antigens; proteins and antibodies
KR101692080B1 (ko) 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법
CN118812712A (zh) 结合人cd137的激动剂抗体及其用途
SK288287B6 (sk) Protilátka proti sekvencii SEQ ID No: 1 alebo polypeptid s jej obsahom a ich použitie
PT808367E (pt) Adressinas vasculares da mucosa e suas utilizações
AU2002360376B2 (en) Modulation of LIR function to treat rheumatoid arthritis
BG108020A (bg) Методи за лечение или профилактика на кожни заболявания с приложение на cd2-свързващи агенти
US6015559A (en) Fas antagonists
AU2002360376A1 (en) Modulation of LIR function to treat rheumatoid arthritis
US7138243B2 (en) NTB-A, a surface molecule involved in natural killer cells activity
US20030021785A1 (en) Use of rank antagonists to treat cancer
WO1999026977A1 (en) Novel receptors opg-2
WO2005060457A2 (en) Treatment of inflammatory bowel diseases with anti-ip-10 antibodies
CA2196431C (en) Icam-4 materials and methods
CA2290067A1 (en) Human tumor necrosis factor receptor-like 2 (tr2) antibodies
US20020102258A1 (en) Human tumor necrosis factor receptor-like 2 (TR2) antibodies
HK1001464B (en) Receptor on the surface of activated t-cells:acts-4
AU1006002A (en) Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
MXPA97003956A (en) Purified genes that codify antigens of surface of mammali cells, proteins and antibody

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued